Young Women’s Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa
Authors:
- the TRIO Study TeamTTthe TRIO Study Team
- Alexandra M. MinnisAMAlexandra M. Minnis
- Sarah T. RobertsSRSarah T. Roberts
- Rachel WeinribRWRachel Weinrib
- Ariane van der StratenASAriane van der Straten
Open Access
- 20 March 2018
- journal article
- research article
- Published by Springer Nature in AIDS and Behavior
- Vol. 22 (8) , 2662-2673
Abstract
End-user input is critical to inform development of multipurpose prevention technology (MPT) products that prevent HIV and pregnancy. The TRIO Study, conducted in Kenya and South Africa, enrolled 277 HIV-negative women aged 18–30 in a randomized cross-over study to use each placebo MPT (daily oral tablets, monthly injections, and monthly vaginal ring) for one month. At the end of each month, participants rated how much they liked using the product on a 5-point Likert scale (5 = liked very much). We compared mean ratings using paired t-tests and examined sociodemographic-, attribute-, and behavior-related characteristics associated with ratings using multivariable linear regression and data from in-depth interviews. After use, mean ratings were significantly higher for injections [4.3 (SD = 1.0)] compared with tablets [3.0 (SD = 1.3)] and rings [3.3 (SD = 1.4)] (p < 0.001); mean ratings for rings were significantly higher than for tablets (p = 0.013). Mean ratings of a hypothetical active MPT increased for all products after the one-month period of use, with the greatest increase for rings, the least familiar product. In multivariable analysis, acceptability of key product attributes (e.g., product look) were associated with a significant increase of ≥ 1 point in the mean rating across all three products (p ≤ 0.001). Perceived ability to use the product without partner knowledge was associated with a higher mean rating for rings (b = 0.50; p = 0.006). The acceptability of product attributes contributed significantly to the rating of all products, highlighting the value of choice in pregnancy and HIV prevention to accommodate diverse users.Keywords
Funding Information
- Bill and Melinda Gates Foundation (OPP1114942)
This publication has 24 references indexed in Scilit:
- Stopping and switching contraceptive methods: findings from Contessa, a prospective longitudinal study of women of reproductive age in EnglandContraception, 2015
- FEM-PrEPJAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
- Lessons from reproductive health to inform multipurpose prevention technologies: Don’t reinvent the wheelAntiviral Research, 2013
- Prioritizing multipurpose prevention technology development and investments using a target product profileAntiviral Research, 2013
- Use of modern contraception increases when more methods become available: analysis of evidence from 1982–2009Global Health: Science and Practice, 2013
- Acceptability in microbicide and PrEP trialsCurrent Opinion in HIV and AIDS, 2012
- Unraveling the divergent results of pre-exposure prophylaxis trials for HIV preventionAIDS, 2012
- Tenofovir-based pre-exposure prophylaxis for HIV preventionCurrent Opinion in Infectious Diseases, 2012
- A Qualitative Study of Obstacles to Diaphragm and Condom Use in an HIV Prevention Trial in Sub-Saharan AfricaAIDS Education and Prevention, 2012
- Family planning and HIV: strange bedfellows no longerAIDS, 2009